The Future of Peptide Development in the Pharmaceutical Industry
Rodney Lax, Ph.D., Senior Director of Business Development North America, PolyPeptide Group
A couple of weeks ago I was asked how long I thought the current interest in peptides as drug candidates would last before another class of molecule replaces them. My answer, based on the potential for new leads from genomics and the length of clinical evaluation, was “about another 20 years”. I realized almost immediately that I have been saying that for at least the last 10 years. Perhaps it is time to re-think this one. Obviously, the interest in developing new peptide therapeutics is going to be around a lot longer.
Read article here:
http://www.polypeptide.com/assets/002/5188.pdf
PYC Price at posting:
5.4¢ Sentiment: LT Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)